Merck, Inc.
🇵🇭Philippines
Phase I Trial of Vorinostat (MK-0683, SAHA) in Combination With Decitabine in Patients With AML or MDS (MK-0683-055 EXT1)
Phase 1
Completed
- Conditions
- Leukemia, Myelocytic, Acute Myelodysplastic SyndromesMyelodysplastic Syndromes
- Interventions
- First Posted Date
- 2007-05-28
- Last Posted Date
- 2015-09-21
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 71
- Registration Number
- NCT00479232
MK-0524B Lipid Study (MK-0524B-063)
Phase 3
Completed
- Conditions
- Primary HypercholesterolemiaMixed Dyslipidemia
- Interventions
- Drug: MK-0524ADrug: PlaceboDrug: MK-0524B
- First Posted Date
- 2007-05-28
- Last Posted Date
- 2019-02-06
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 2414
- Registration Number
- NCT00479882
Safety and Efficacy of Sugammadex (Org 25969, MK-8616) in Participants With or Having a Past History of Pulmonary Disease (19.4.308) (P05932) (MK-8616-017)
- First Posted Date
- 2007-05-21
- Last Posted Date
- 2019-04-12
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 86
- Registration Number
- NCT00475215
A Study to Test the Safety and Efficacy of MK0249 in Patients With ADHD (0249-018)(COMPLETED)
Phase 2
Completed
- Conditions
- Attention-Deficit/Hyperactivity Disorder (ADHD)
- Interventions
- First Posted Date
- 2007-05-21
- Last Posted Date
- 2015-07-28
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 72
- Registration Number
- NCT00475735
Comparison of the Efficacy, Safety, and Pharmacokinetics of Sugammadex (MK-8616; Org 25969) in Elderly Participants With Adult Participants (MK-8616-029)
- First Posted Date
- 2007-05-17
- Last Posted Date
- 2019-04-02
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 162
- Registration Number
- NCT00474617
Vicriviroc in HIV-Treatment Experienced Subjects (Study P04889AM8)(COMPLETED)
Phase 3
Completed
- Conditions
- HIV InfectionsAcquired Immunodeficiency Syndrome
- Interventions
- Drug: PlaceboDrug: Vicriviroc
- First Posted Date
- 2007-05-16
- Last Posted Date
- 2022-08-30
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 400
- Registration Number
- NCT00474370
A Clinical Trial of Vorinostat (MK0683, SAHA) in Combination With FDA Approved Cancer Drugs in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)(0683-056)
- First Posted Date
- 2007-05-16
- Last Posted Date
- 2015-07-03
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 253
- Registration Number
- NCT00473889
Comparison of Recovery From Rocuronium 1.2 mg/kg Followed by Sugammadex (Org 25969) 16 mg/kg at 3 Minutes With Recovery From Succinylcholine 1.0 mg/kg (19.4.303)(P05946)(MK-8616-026)
Phase 3
Completed
- Conditions
- Anesthesia, General
- Interventions
- First Posted Date
- 2007-05-16
- Last Posted Date
- 2019-04-11
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 115
- Registration Number
- NCT00474253
Comparison of Sugammadex (MK-8616/Org 25969) With Neostigmine Administered at 1-2 Post-tetanic Counts (PTCs) After Administration of Rocuronium or Vecuronium (19.4.302/P05945/MK-8616-025)
Phase 3
Completed
- Conditions
- Anesthesia, General
- Interventions
- First Posted Date
- 2007-05-15
- Last Posted Date
- 2019-03-19
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 182
- Registration Number
- NCT00473694
A Study of V950 in People With Alzheimer Disease (V950-001 AM7)
Phase 1
Completed
- Conditions
- Alzheimer Disease
- Interventions
- Biological: ISCOMATRIX™Biological: V950Biological: Placebo to V950
- First Posted Date
- 2007-04-23
- Last Posted Date
- 2015-09-25
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 86
- Registration Number
- NCT00464334
© Copyright 2025. All Rights Reserved by MedPath